Novo Nordisk announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25. Key data presentations across both hemophilia A and B (HA and HB), with and without inhibitors, will share insights on clotting, thrombin generation, bleeding episodes and medication impact, patient administration preferences, physician treatment satisfaction and global real-world diagnosis and treatment data for joint bleeds.
Hemophilia is a rare, inherited bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. It is estimated to affect approximately 1,125,000 people worldwide.
“At Novo Nordisk, we believe understanding the whole person and their journey is essential to addressing the unmet needs in people with hemophilia. Our research is rooted in a deep understanding of the hemophilia community, aiming to drive critical advancements across rare blood disorders in order to help address these unmet needs,” said Stephanie Seremetis, chief medical officer and CVP for Rare Disease at Novo Nordisk. “Through this latest research, we are honored to build on our long-standing legacy in rare blood disorders to support patients who face the challenges of this complex condition.”
New phase 3 data will be presented on Mim8, an investigational mimetic therapy designed to replicate the function of missing clotting factors. 1Analysis from the phase 3 FRONTIER5 trial will assess the safety and preferences of people with HA, with and without inhibitors, who switch from emicizumab to Mim8.
In addition, new data from two prospective, multicenter, open label, phase 3 trials (explorer7 and explorer8) will investigate joint bleeds, non-joint bleeds and annualized bleeding rate with preventive concizumab being investigated versus on-demand treatment across both HA and HB, with and without inhibitors.
Additional information can be found on the ISTH website.
1 Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268.
